REFERENCES
- Burnett, AK. (1999) "Tailoring the treatment of acute myeloid leukemia", Current Opinion in Hematology, 6, 247 — 252.
- Lowenberg, B., Downing, J.R. and Burnett, A. (1999) "Acute myeloid leukemia", New England Journal of Medicine, 341, 1051 — 1062.
- Freireich, E.J. (1998) "Four decades of therapy for AML", Leukemia, 12\(Suppl 1), S54 —S56.
- Cummings, J. and Smyth, J.F. (1993) "DNA topoisomerase I and II as targets for rational design of new anticancer drugs", Annals of Oncology, 4, 533 — 543.
- Hendricks, C.B., Rowinsky, E.K., Grochow, LB., Donehower, R.C. and Kaufmann, S.H. (1992) "Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue", Cancer Research, 52, 2268–2278.
- Kantarjian, H.M., Beran, M., Ellis, A., Zwelling, L., O'Brien, S., Cazenave, L., et al. (1993) "Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia", Blood, 81, 1146–1151.
- Rowinsky, E.K., Adjei, A., Donehower, R.C., Gore, S.D., Jones, R.J., Burke, P.J., et al. (1994) "Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia", Journal of Clinical Oncology, 12, 2193— 2203.
- Seiter, K., Feldman, E.J., Halicka, H.D., Traganos, F., Darzynkie-wicz, Z., Lake, D., et al. (1997) "Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia", Journal of Clinical Oncology, 15, 44–51.
- Kern, W., Schleyer, E., Braess, J., Wittmer, E., Ohnesorge, J., Unterhalt, M., et al. (2001) "Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias", Annals of Hematology, 80, 334— 339.
- Buchner, T., Hiddemann, W., Wormann, B., Loftier, H., Gassmann, W., Haferlach, T., et al. (1999) "Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxan-trone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group", Blood, 93, 4116 — 4124.
- Beran, M., Kantarjian, H., O'Brien, S., Koller, C., al Bitar, M., Arbuck, S., et al. (1996) "Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia", Blood, 88, 2473–2479.
- Beran, M., Estey, E., O'Brien, S., Cortes, J., Koller, CA., Giles, F.J., et al. (1999) "Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia", Journal of Clinical Oncology, 17, 2819 — 2830.